Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Scientific v. Medinol

This article was originally published in The Gray Sheet

Executive Summary

Manhattan federal court rules Medinol is entitled to try its claims that Boston Scientific's sales of Taxus and Express stents are a breach of contract, entitling it to royalties, the Israeli firm states Dec. 2. A status conference is slated for Jan. 13 to set a trial date. Medinol developed and manufactured stents for Boston Scientific beginning in 1995 until the relationship soured in 2000, when Boston Scientific revealed a secret project - called "Project Independence" - under which it shifted its manufacturing and R&D programs in-house by building a plant in Galway, Ireland (1"The Gray Sheet" April 8, 2002, p. 14). Boston Scientific says the court's ruling will not interfere with Taxus paclitaxel-eluting stent sales. In a Dutch court, Medinol recently sought a 30% royalty from Boston Scientific on all past and future sales of Taxus in and from The Netherlands (2"The Gray Sheet" Feb. 16, 2004, p. 20)...

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts